There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes. The success of CAR-T technology for the treatment of haematology cancers has been a glowing example of the power of molecular manipulation to treat specific conditions.
More than three dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. Efforts to re-focus and apply this technology to solid tumours is now aggressively being pursued by a growing list of market participants. This report examines leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.
More than three dozen targeted treatments, using novel pathways and signalling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological, and emotional burden of cancer. Efforts to re-focus and apply this technology to solid tumours is now aggressively being pursued by a growing list of market participants. This report examines leading mAb and kinase inhibitor therapeutic drugs and the biomarkers they utilize.
Target Oncology Haematology Cancers - What You Will Learn
- What is the market share of approved haematology cancer therapeutics?
- What is the global supply picture for targeted haematology cancer therapeutics?
- Who are the market leaders, by Indication? by Product?
- What is the therapeutic coverage across all oncology indications? What are the product opportunities?
- What are the established products in this space? by target, indication, API class, revenue?
- What is the competitive picture for the haematology cancer market segments?
- Drug treatment resources
- Competitive therapy map
- Clinical trial activity
- Who are the leading competitors in the field of next-generation haematology cancer therapeutics?
Table of Contents
- Executive Summary
- Targeted Oncology Therapeutics
- Hematology Cancers
- Executive Summary
- The Recombinant Drug Ecosystem
- mAbs and Targeted Oncology Therapeutics
- Leukemias
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Childhood Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia
- Lymphomas
- Hodgkin Lymphoma
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
- Biological Drugs for Hematology Cancers
- Monoclonal Antibodies (Twelve Therapeutic Products)
- Tyrosine Kinase Inhibitors
- ALL with Philadelphia chromosome (Ph+ ALL)
- FDA Approved TKIs (Six Therapeutic Products)
- Chimeric Antigen Receptor-T (CAR-T) (Five Products)
- The Therapeutic Market Landscape
- Diagnostic Tools
- Drugs in Development - The Clinical Trial Picture
- Leukemias
- Lymphomas
- Myeloma
- FDA-Approved Targeted Oncology
- Therapeutics for Hematology Cancers
Companies Mentioned
- Amgen
- Astellas
- AstraZeneca
- Bristol-Myers Squibb
- Celltrion
- Daiichi Sankyo
- Eli Lilly
- Genentech
- Genzyme
- GlaxoSmithKline
- Janssen Biotech
- Kyowa Kirin
- Merck Sharp & Dohme
- Mylan GmbH
- Pfizer
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Spetrum Pharmaceuticals
- United Therapeutics
- Roche
- EMD Serono
- Immunex
- Lonza Biologics
- Lonza AG
- Seattle Genetics
- Biogen
